Celgene Corp (CELG)

105.50
2.00 1.90
NASDAQ : Health Care
Prev Close 107.52
Open 107.44
Day Low/High 106.73 / 108.14
52 Wk Low/High 92.98 / 137.54
Volume 3.31M
Avg Volume 4.38M
Exchange NASDAQ
Shares Outstanding 774.60M
Market Cap 83.23B
EPS 2.00
P/E Ratio 51.91
Div & Yield N.A. (N.A)

Latest News

Bullish and Bearish Reversals for the Week

Bullish and Bearish Reversals for the Week

Chipotle, Wendy's on the bull side and gold stocks on the bear side.

Jim Cramer's 'Mad Money' Recap: Here's What I'm Watching Next Week

Jim Cramer's 'Mad Money' Recap: Here's What I'm Watching Next Week

Cramer is gearing up for the heaviest week of this earnings season, but he's also providing his game plan for helping you be a better investor.

Celgene (CELG) Stock Is the ‘Chart of the Day’

Celgene (CELG) Stock Is the ‘Chart of the Day’

TheStreet’s Chris Versace and Bob Lang said biotech companies like Celgene (CELG) are slowly but surely staging a quiet resurgence.

Chart of the Day: Celgene

Celgene is showing relative strength on a weak market day.

ECB Decision a Dud

It denies higher prices to late-to-the-party bulls who need another lift to turn red into green.

Celgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pact

Celgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pact

Celgene continues to sprinkle cash around the biotech sector, tying up with smaller companies for first-dibs access to potentially valuable drugs and technologies.

Celgene (CELG) Is Strong On High Volume Today

Celgene (CELG) Is Strong On High Volume Today

Trade-Ideas LLC identified Celgene (CELG) as a strong on high relative volume candidate

5 Toxic Stocks to Sell as Anxiety Creeps Higher

5 Toxic Stocks to Sell as Anxiety Creeps Higher

It's time to unload these toxic stocks from your portfolio.

Could the Dow Jump Up Another 400 Points by Year-End?

Could the Dow Jump Up Another 400 Points by Year-End?

Concerns that the market is overvalued continue to arise as the S&P 500 has increased by 7.6% during the past two weeks. But there may still be room for growth.

Next Up for Celgene's Crohn's Pill: A Snapshot Inside Patients' Colons

Next Up for Celgene's Crohn's Pill: A Snapshot Inside Patients' Colons

GED-0301 is one of three drugs -- Otezla and ozanimod are the others -- which form the core of Celgene's burgeoning immunology and inflammation franchise.

Biotechs and Builders Will Rock 2Q Earnings

Biotechs and Builders Will Rock 2Q Earnings

A look at who will be up and who will down this earnings season.

Cramer: 10 Stocks That Need to Start Doing Better

Cramer: 10 Stocks That Need to Start Doing Better

They need to do something that makes them stand out as stocks you want to own, not avoid.

CELG, REGN, DPZ: Jim Cramer's Views

CELG, REGN, DPZ: Jim Cramer's Views

Cramer shares his views on why something could be up in biotech, restaurants and retail. Celgene, Regeneron and Domino's are among the stocks discussed.

Celgene Shares Likely to Jump on Potential $2B 'Orphan' Drug: RBC

Celgene Shares Likely to Jump on Potential $2B 'Orphan' Drug: RBC

Shareholders could be in for a surprise if an upcoming drug for pediatric Crohn's gains FDA approval.

5 Stocks I Like for 2016's Second Half

From Celgene to Ford, these names look promising.

Medivation Tries to Prove Its Worth

Medivation Tries to Prove Its Worth

A call with investors Wednesday highlights drugs in the pipeline that could be attractive to bidders that reportedly include Sanofi, Pfizer and Celgene, among others.

Wall Street Closes Higher as Fed Doves Make Case for Waiting on Rates

Wall Street Closes Higher as Fed Doves Make Case for Waiting on Rates

A dovish Federal Reserve in June pushes equities, crude to close around session highs.

Stocks Add to Gains as Fed Stresses Prudence in Policy-Making

Stocks Add to Gains as Fed Stresses Prudence in Policy-Making

Stocks add to gains by late afternoon Wednesday after the Federal Reserve's June meeting minutes confirm members' prudent approach to monetary policy.

Cramer: Might Something Be Brewing in 3 Downtrodden Sectors?

Biotech, restaurants and retail have been left for dead but are showing signs of life today.

Medivation Shares Spike as Company Opens Door to Full-Fledged Auction

Medivation Shares Spike as Company Opens Door to Full-Fledged Auction

The company's shares were up nearly 2% in after hours trading.

Stocks Feeling the Pressure of 'Brexit', Italian Banks Weakness

Stocks Feeling the Pressure of 'Brexit', Italian Banks Weakness

There are renewed worries about Brexit as the British pound has fallen to a new 30 year low.

An Auction Process Could Be on Medivation's Horizon

An Auction Process Could Be on Medivation's Horizon

The biopharmaceutical company has entered into confidentiality agreements with Sanofi and others.

The Week's Events Were a Reset, and Bonds Are the Key to the Markets: Best of Kass

The Week's Events Were a Reset, and Bonds Are the Key to the Markets: Best of Kass

In highlights from this week's trading diary and posts, Kass tells us that bankers are feckless and that a blow-off could come with a major cycle end.

Celgene Corporation To Announce Second Quarter 2016 Results On July 28, 2016

Celgene Corporation To Announce Second Quarter 2016 Results On July 28, 2016

Celgene Corporation (NASDAQ:CELG) will host a conference call and live audio webcast on Thursday, July 28, 2016 at 9 a.

Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here

Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

How Pfizer, Merck May Feel Long-Term Pinch From Brexit

How Pfizer, Merck May Feel Long-Term Pinch From Brexit

The eventual negative implications of Brexit could be greater for health care companies that have sizable exposure to Europe.

Brexit Bargain Buys: 14 More Stocks Picked by Morgan Stanley

Brexit Bargain Buys: 14 More Stocks Picked by Morgan Stanley

The Brexit-related market pullback has created stock-buying opportunities. Here are 14 more stocks for investors to consider from Morgan Stanley.